38 related articles for article (PubMed ID: 9520947)
1. Amplicon rearrangements during the extrachromosomal and intrachromosomal amplification process in a glioma.
Vogt N; Gibaud A; Lemoine F; de la Grange P; Debatisse M; Malfoy B
Nucleic Acids Res; 2014 Dec; 42(21):13194-205. PubMed ID: 25378339
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer.
Shimizu H; Kochi M; Fujii M; Watabe M; Matsuno Y; Kawai T; Suda H; Tanino T; Nakanishi Y; Masuda S; Okamura Y
Discov Oncol; 2023 Jun; 14(1):111. PubMed ID: 37354221
[TBL] [Abstract][Full Text] [Related]
3. The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers.
Majumder A; Sandhu M; Banerji D; Steri V; Olshen A; Moasser MM
Sci Rep; 2021 Apr; 11(1):9091. PubMed ID: 33907275
[TBL] [Abstract][Full Text] [Related]
4. Targeting HER2 by Combination Therapies.
Ruiz-Saenz A; Moasser MM
J Clin Oncol; 2018 Mar; 36(8):808-811. PubMed ID: 29381433
[No Abstract] [Full Text] [Related]
5. Letter in response to "Our HER2 is same as yours".
Matsusaka S; Yoshida K
Transl Gastroenterol Hepatol; 2016; 1():18. PubMed ID: 28138585
[No Abstract] [Full Text] [Related]
6. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
[TBL] [Abstract][Full Text] [Related]
7. Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.
Kochi M; Fujii M; Masuda S; Kanamori N; Mihara Y; Funada T; Tamegai H; Watanabe M; Suda H; Takayama T
Diagn Pathol; 2013 Nov; 8():191. PubMed ID: 24261710
[TBL] [Abstract][Full Text] [Related]
8. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
9. Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.
Zheng Y; Wang L; Zhang JP; Yang JY; Zhao ZM; Zhang XY
World J Gastroenterol; 2010 Jan; 16(3):339-44. PubMed ID: 20082479
[TBL] [Abstract][Full Text] [Related]
10. EGFR and HER2 expression in advanced biliary tract cancer.
Harder J; Waiz O; Otto F; Geissler M; Olschewski M; Weinhold B; Blum HE; Schmitt-Graeff A; Opitz OG
World J Gastroenterol; 2009 Sep; 15(36):4511-7. PubMed ID: 19777609
[TBL] [Abstract][Full Text] [Related]
11. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.
Barros-Silva JD; Leitão D; Afonso L; Vieira J; Dinis-Ribeiro M; Fragoso M; Bento MJ; Santos L; Ferreira P; Rêgo S; Brandão C; Carneiro F; Lopes C; Schmitt F; Teixeira MR
Br J Cancer; 2009 Feb; 100(3):487-93. PubMed ID: 19156142
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
13. Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.
Yao T; Utsunomiya T; Oya M; Nishiyama K; Tsuneyoshi M
World J Gastroenterol; 2006 Apr; 12(16):2510-6. PubMed ID: 16688795
[TBL] [Abstract][Full Text] [Related]
14. The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction.
Barrans SL; Evans PA; O'Connor SJ; Owen RG; Morgan GJ; Jack AS
J Mol Diagn; 2003 Aug; 5(3):168-75. PubMed ID: 12876207
[TBL] [Abstract][Full Text] [Related]
15. Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.
Ooi A; Kobayashi M; Mai M; Nakanishi I
Lab Invest; 1998 Mar; 78(3):345-51. PubMed ID: 9520947
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization.
Ishikawa T; Kobayashi M; Mai M; Suzuki T; Ooi A
Am J Pathol; 1997 Sep; 151(3):761-8. PubMed ID: 9284825
[TBL] [Abstract][Full Text] [Related]
17. Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization.
Hara T; Ooi A; Kobayashi M; Mai M; Yanagihara K; Nakanishi I
Lab Invest; 1998 Sep; 78(9):1143-53. PubMed ID: 9759658
[TBL] [Abstract][Full Text] [Related]
18. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study.
Hirashima N; Takahashi W; Yoshii S; Yamane T; Ooi A
Mod Pathol; 2001 Jun; 14(6):556-62. PubMed ID: 11406656
[TBL] [Abstract][Full Text] [Related]
19. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
